# Evaluation of XYA02 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07670312/  
OnCo record `nct07670312` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by XYone Therapeutics, Inc, not yet recruiting.

## Summary

Evaluation of XYA02 in Patients With Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07670312 by XYone Therapeutics, Inc, with a registry enrolment figure of 190 participants, started 2026-07-15 and due to reach its primary completion in 2029-07-15. Interventions recorded: XYA02. Conditions listed: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; GEJ Adenocarcinoma; Colorectal Cancer; Pancreatic Adenocarcinoma. Primary outcome: Frequency of Treatment Emergent Adverse Events of XYA02; Duration of Treatment Emergent Adverse Events of XYA02; Severity of Treatment Emergent Adverse Events of XYA02. Pancreatic eligibility wording from the registry: "Cohort 2E: Pancreatic cancer". Sites: Australia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07670312
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors
- Sponsor: XYone Therapeutics, Inc
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT07670312: https://clinicaltrials.gov/study/NCT07670312

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07670312.json